Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74.
Article
CAS
Google Scholar
O'Leary B, Finn RS, Turner NC. Treating cancer with selective CDK4/6 inhibitors. Nat Rev Clin Oncol. 2016;13(7):417–30.
Article
CAS
Google Scholar
Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer. 2009;9(3):153–66.
Article
CAS
Google Scholar
Dean JL, Thangavel C, McClendon AK, Reed CA, Knudsen ES. Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure. Oncogene. 2010;29(28):4018–32.
Article
CAS
Google Scholar
Osborne CK, Schiff R. Mechanisms of endocrine resistance in breast cancer. Annu Rev Med. 2011;62:233–47.
Article
CAS
Google Scholar
Bosco EE, Knudsen ES. RB in breast cancer: at the crossroads of tumorigenesis and treatment. Cell Cycle. 2007;6(6):667–71.
Article
CAS
Google Scholar
Turner NC, Slamon DJ, Ro J, Bondarenko I, Im SA, Masuda N, et al. Overall survival with Palbociclib and Fulvestrant in advanced breast Cancer. N Engl J Med. 2018;379(20):1926–36.
Article
CAS
Google Scholar
Slamon DJ, Neven P, Chia S, Fasching PA, De Laurentiis M, Im SA, et al. Phase III randomized study of Ribociclib and Fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast Cancer: MONALEESA-3. J Clin Oncol. 2018;36(24):2465–72.
Article
CAS
Google Scholar
Sledge GW Jr, Toi M, Neven P, Sohn J, Inoue K, Pivot X, et al. The effect of Abemaciclib plus Fulvestrant on overall survival in hormone receptor–positive, ERBB2-negative breast Cancer that progressed on endocrine therapy—MONARCH 2: a randomized clinical trial. JAMA Oncol. 2020;6(1):116–24.
Article
Google Scholar
Cristofanilli M, Turner NC, Bondarenko I, Ro J, Im SA, Masuda N, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. 2016;17(4):425–39.
Article
CAS
Google Scholar
Sledge GW Jr, Toi M, Neven P, Sohn J, Inoue K, Pivot X, et al. MONARCH 2: Abemaciclib in combination with Fulvestrant in women with HR+/HER2- advanced breast Cancer who had progressed while receiving endocrine therapy. J Clin Oncol. 2017;35(25):2875–84.
Article
CAS
Google Scholar
Finn RS, Martin M, Rugo HS, Jones S, Im S-A, Gelmon K, et al. Palbociclib and Letrozole in advanced breast Cancer. N Engl J Med. 2016;375(20):1925–36.
Article
CAS
Google Scholar
Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, et al. Ribociclib as first-line therapy for HR-positive, advanced breast Cancer. N Engl J Med. 2016;375(18):1738–48.
Article
CAS
Google Scholar
Tripathy D, Im SA, Colleoni M, Franke F, Bardia A, Harbeck N, et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol. 2018;19(7):904–15.
Article
CAS
Google Scholar
Goetz MP, Toi M, Campone M, Sohn J, Paluch-Shimon S, Huober J, et al. MONARCH 3: Abemaciclib as initial therapy for advanced breast Cancer. J Clin Oncol. 2017;35(32):3638–46.
Article
CAS
Google Scholar
Dickler MN, Tolaney SM, Rugo HS, Cortés J, Diéras V, Patt D, et al. MONARCH 1, a phase II study of Abemaciclib, a CDK4 and CDK6 inhibitor, as a single agent, in patients with refractory HR(+)/HER2(−) metastatic breast Cancer. Clin Cancer Res. 2017;23(17):5218–24.
Article
CAS
Google Scholar
Wang J, Li Q, Yuan J, Wang J, Chen Z, Liu Z, et al. CDK4/6 inhibitor-SHR6390 exerts potent antitumor activity in esophageal squamous cell carcinoma by inhibiting phosphorylated Rb and inducing G1 cell cycle arrest. J Transl Med. 2017;15(1):127.
Article
Google Scholar
Long F, He Y, Fu H, Li Y, Bao X, Wang Q, et al. Preclinical characterization of SHR6390, a novel CDK 4/6 inhibitor, in vitro and in human tumor xenograft models. Cancer Sci. 2019;110(4):1420–30.
Article
CAS
Google Scholar
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47.
Article
CAS
Google Scholar
Bellet M, Ahmad F, Villanueva R, Valdivia C, Palomino-Doza J, Ruiz A, et al. Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication. Ther Adv Med Oncol. 2019;11:1758835919833867.
Article
CAS
Google Scholar
Schwartz GK, LoRusso PM, Dickson MA, Randolph SS, Shaik MN, Wilner KD, et al. Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (schedule 2/1). Br J Cancer. 2011;104(12):1862–8.
Article
CAS
Google Scholar
Infante JR, Cassier PA, Gerecitano JF, Witteveen PO, Chugh R, Ribrag V, et al. A phase I study of the Cyclin-dependent kinase 4/6 inhibitor Ribociclib (LEE011) in patients with advanced solid tumors and lymphomas. Clin Cancer Res. 2016;22(23):5696–705.
Article
CAS
Google Scholar
DeMichele A, Clark AS, Tan KS, Heitjan DF, Gramlich K, Gallagher M, et al. CDK 4/6 inhibitor palbociclib (PD0332991) in Rb+ advanced breast cancer: phase II activity, safety, and predictive biomarker assessment. Clin Cancer Res. 2015;21(5):995–1001.
Article
CAS
Google Scholar
Malorni L, Curigliano G, Minisini AM, Cinieri S, Tondini CA, D'Hollander K, et al. Palbociclib as single agent or in combination with the endocrine therapy received before disease progression for estrogen receptor-positive, HER2-negative metastatic breast cancer: TREnd trial. Ann Oncol. 2018;29(8):1748–54.
Article
CAS
Google Scholar
Asghar U, Witkiewicz AK, Turner NC, Knudsen ES. The history and future of targeting cyclin-dependent kinases in cancer therapy. Nat Rev Drug Discov. 2015;14(2):130–46.
Article
CAS
Google Scholar
Groenland SL, Martínez-Chávez A, van Dongen MGJ, Beijnen JH, Schinkel AH, Huitema ADR, et al. Clinical pharmacokinetics and pharmacodynamics of the Cyclin-dependent kinase 4 and 6 inhibitors Palbociclib, Ribociclib, and Abemaciclib. Clin Pharmacokinet. 2020;59(12):1501–20.
Article
Google Scholar
Fogli S, Del Re M, Curigliano G, van Schaik RH, Lancellotti P, Danesi R. Drug-drug interactions in breast cancer patients treated with CDK4/6 inhibitors. Cancer Treat Rev. 2019;74:21–8.
Article
CAS
Google Scholar
US Food and Drug Administration: FDA warns about rare but severe lung inflammation with Ibrance, Kisqali, and Verzenio for breast cancer. 2019. https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-about-rare-severe-lung-inflammation-ibrance-kisqali-and-verzenio-breast-cancer. Accessed 02 Feb, 2021.